This Article Full Text Full Text (PDF) Supplemental material Other Versions of this Article: JCM.00431-07v1 45/8/2604    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Lalonde, M. S. Articles by Arts, E. J. Search for Related Content PubMed PubMed Citation Articles by Lalonde, M. S. Articles by Arts, E. J.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, August 2007, p. 2604-2615, Vol. 45, No. 8
0095-1137/07/$08.00+0     doi:10.1128/JCM.00431-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Sensitive Oligonucleotide Ligation Assay for Low-Level Detection of Nevirapine Resistance Mutations in Human Immunodeficiency Virus Type 1 Quasispecies ^,

Division of Infectious Diseases, Department of Medicine, Case Western Reserve University, Cleveland, Ohio 44106,¹ Joint Clinical Research Centre, Kampala, Uganda,² Mbarara University, Mbarara, Uganda³

Received 24 February 2007/ Returned for modification 12 April 2007/ Accepted 4 June 2007

This study has adapted the oligonucleotide ligation assay (OLA) to probe for low-level nevirapine (NVP) resistance mutations K103N and Y181C in the human immunodeficiency virus type 1 (HIV-1) population of infected mother-infant pairs from Uganda. When NVP is used to prevent perinatal transmission, NVP-resistant HIV-1 clones may be rapidly selected due to a low barrier for mutation and a relatively high level of fitness (compared to that of other drug-resistant HIV-1 clones). Monitoring for even a low frequency of NVP resistance mutations may help predict the success of subsequent treatment or warrant the use of another regimen to prevent transmission in a subsequent pregnancy. The standard OLA was optimized by using nonstandard bases in oligonucleotides to allow promiscuous base pairing and accommodate significant HIV-1 heterogeneity. Radiolabeled as opposed to fluorescently tagged oligonucleotides increased the sensitivity, whereas alteration of the template, oligonucleotides, salt, and thermostable DNA ligase concentrations increased the specificity for the detection of minority codons. This modified OLA is now capable of detecting mutants with the K103N or the Y181C mutation present in an HIV-1 population at a frequency of 0.4% and is at least 10- to 30-fold more sensitive than the original protocol. A cohort of 19 Ugandan mothers who received NVP treatment perinatally were sampled 6 weeks postdelivery. Ten of 19 HIV-1 DNA samples extracted from peripheral blood mononuclear cells had a detectable K103N (0.5 to 44%) or Y181C (0.8 to 92.5%) mutation, but only one plasma HIV-1 RNA sample had a viral population with the Y181C mutation. These findings suggest that OLA is a robust, sensitive, and specific method for the detection of low-frequency drug resistance mutations in an intrapatient HIV-1 population.

Published ahead of print on 13 June 2007.

Supplemental material for this article may be found at http://jcm.asm.org/.